Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group

BACKGROUND: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gampenrieder, S.P., Dezentjé, V., Lambertini, M., de Nonneville, A., Marhold, M., Le Du, F., Cortés Salgado, A., Alpuim Costa, D., Vaz Batista, M., Chic Ruché, N., Tinchon, C., Petzer, A., Blondeaux, E., Del Mastro, L., Targato, G., Bertucci, F., Gonçalves, A., Viret, F., Bartsch, R., Mannsbart, C., Deleuze, A., Robert, L., Saavedra Serrano, C., Gion Cortés, M., Sampaio-Alves, M., Vitorino, M., Pecen, L., Singer, C., Harbeck, N., Rinnerthaler, G., Greil, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024122/
https://www.ncbi.nlm.nih.gov/pubmed/36563519
http://dx.doi.org/10.1016/j.esmoop.2022.100747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024122/
https://www.ncbi.nlm.nih.gov/pubmed/36563519
http://dx.doi.org/10.1016/j.esmoop.2022.100747

Ejemplares similares